Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TEVA Teva Pharmaceutical Industries Ltd
- Stocks
- Healthcare
- NYSE: TEVA
Price (delayed)
$16.8
Market cap
$19.27B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.14
Enterprise value
$34.51B
Highlights
The debt has declined by 15% year-on-year and by 6% since the previous quarter
TEVA's revenue is up by 3.8% year-on-year
TEVA's net income has dropped by 168% year-on-year but it is up by 22% since the previous quarter
Teva Pharmaceutical Industries's EPS has shrunk by 165% YoY but it has increased by 21% QoQ
TEVA's quick ratio is down by 8% from the previous quarter and by 2.1% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.tevapharm.com
Key stats
What are the main financial stats of TEVA
Market
Valuations
Earnings
Shares outstanding
1.15B
Market cap
$19.27B
Enterprise value
$34.51B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.04
Price to sales (P/S)
1.15
EV/EBIT
73.27
EV/EBITDA
22.98
EV/Sales
2.08
Revenue
$16.62B
Gross profit
$8.17B
Operating income
$429M
Net income
-$1.29B
EBIT
$471M
EBITDA
$1.5B
Free cash flow
$765M
Per share
Balance sheet
Liquidity
EPS
-$1.14
EPS diluted
-$1.15
Free cash flow per share
$0.67
Book value per share
$5.52
Revenue per share
$14.6
TBVPS
$16.48
Total assets
$38.42B
Total liabilities
$32.15B
Debt
$16.94B
Equity
$6.26B
Working capital
$371M
Debt to equity
2.71
Current ratio
1.03
Quick ratio
0.46
Net debt/EBITDA
10.15
Margins
Efficiency
Dividend
EBITDA margin
9%
Gross margin
49.2%
Net margin
-7.7%
Operating margin
2.6%
Return on assets
-3.2%
Return on equity
-21.4%
Return on invested capital
2.1%
Return on capital employed
1.7%
Return on sales
2.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TEVA stock price
How has the Teva Pharmaceutical Industries stock price performed over time
Intraday
-3.89%
1 week
-4.55%
1 month
23.53%
1 year
-1.7%
YTD
-23.77%
QTD
9.3%
Financial performance
How have Teva Pharmaceutical Industries's revenue and profit performed over time
Revenue
$16.62B
Gross profit
$8.17B
Operating income
$429M
Net income
-$1.29B
Gross margin
49.2%
Net margin
-7.7%
TEVA's net income has dropped by 168% year-on-year but it is up by 22% since the previous quarter
The net margin has dropped by 157% year-on-year but it has increased by 22% since the previous quarter
The operating margin has soared by 100% YoY
TEVA's operating income has soared by 99% YoY
Price vs fundamentals
How does TEVA's price correlate with its fundamentals
Growth
What is Teva Pharmaceutical Industries's growth rate over time
Valuation
What is Teva Pharmaceutical Industries stock price valuation
P/E
N/A
P/B
3.04
P/S
1.15
EV/EBIT
73.27
EV/EBITDA
22.98
EV/Sales
2.08
Teva Pharmaceutical Industries's EPS has shrunk by 165% YoY but it has increased by 21% QoQ
TEVA's price to book (P/B) is 86% higher than its 5-year quarterly average of 1.7 but 7% lower than its last 4 quarters average of 3.4
Teva Pharmaceutical Industries's equity has increased by 17% QoQ but it has decreased by 14% YoY
The P/S is 50% above the 5-year quarterly average of 0.8
TEVA's revenue is up by 3.8% year-on-year
Efficiency
How efficient is Teva Pharmaceutical Industries business performance
Teva Pharmaceutical Industries's return on assets has shrunk by 191% YoY but it has increased by 20% QoQ
TEVA's ROE is up by 18% from the previous quarter
Teva Pharmaceutical Industries's return on sales has decreased by 15% YoY
Dividends
What is TEVA's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history
Special dividends are included in TTM DPS and yield
Financial health
How did Teva Pharmaceutical Industries financials performed over time
The total assets is 20% greater than the total liabilities
Teva Pharmaceutical Industries's current ratio has increased by 16% YoY and by 5% QoQ
The total assets is down by 10% year-on-year and by 2.3% since the previous quarter
The debt is 171% greater than the equity
TEVA's debt to equity is down by 19% from the previous quarter
Teva Pharmaceutical Industries's equity has increased by 17% QoQ but it has decreased by 14% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.